⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HRMY News
Harmony Biosciences Holdings, Inc. Common Stock
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
globenewswire.com
HRMY
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
businesswire.com
HRMY
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
businesswire.com
HRMY
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
businesswire.com
HRMY
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
businesswire.com
HRMY
Harmony Biosciences to Participate in Upcoming Investor Conferences
businesswire.com
HRMY
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
businesswire.com
HRMY
Harmony Biosciences to Present Rare Epilepsy Data at the 36 th International Epilepsy Congress
businesswire.com
HRMY